Roche receives CE Mark for Ventana FOLR1 RxDx Assay
Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...
Roche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay Gets CE Mark In Ovarian Cancer Treatment
Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...
GlobalData on MSN1mon
Roche’s VENTANA CLDN18 assay gains CE mark
Roche has gained the Conformité Européenne (CE) mark of approval for its VENTANA CLDN18 (43-14A) RxDx assay to identify ...
Yahoo Finance1mon
Roche receives FDA approval for Ventana CLDN18 RxDx Assay
Roche (RHHBY) announced that the VENTANA CLDN18 RxDx Assay is the first U.S. Food and Drug Administration approved immunohistochemistry companion diagnostic for determining CLDN18 protein ...
Pharmabiz1mon
Roche’s IHC companion diagnostic test, VENTANA CLDN18 (43-14A) RxDx Assay to identify patients with gastric or GEJ cancer gets CE Mark approval
Roche announced that the VENTANA CLDN18 (43-14A) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive CE Mark approval for determining CLDN18 protein expression in ...
GlobalData on MSN28d
FDA approves Astellas’ VYLOY for gastric cancer treatment
This is the first US approval for VYLOY, a therapy targeting claudin (CLDN)-18.2-positive tumours identified through an ...
Morningstar1mon
Roche Gets FDA Approval for Cancer Diagnostic Test
The diagnostic, called the Ventana CLDN18 (43-14A) RxDx Assay, can help determine the status of Claudin 18 protein expression in tumors of cancer patients, helping inform clinicians about the ...
Nasdaq1mon
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
1 The VENTANA CLDN18 (43-14A) RxDx Assay from Roche is an FDA-approved IHC test used to help determine CLDN18.2 status. Testing is available in the U.S. at multiple reference laboratories ...
Monthly Prescribing Reference1mon
Vyloy Approved for Gastric and Gastroesophageal Junction Cancer
In clinical trials, CLDN18.2 positivity was determined by immunohistochemistry on gastric or GEJ tumor tissue specimens with the Ventana CLDN18 (43-14A) RxDx Assay. The Food and Drug ...
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha ...
MarketWatch1mon
Roche Gets FDA Approval for Cancer Diagnostic Test
Roche Holdings said it received Food and Drug Administration approval for its companion diagnostic of gastric and gastroesophageal junction cancer. The diagnostic, called the Ventana CLDN18 (43 ...